Amarin Pharmaceuticals, Inc.

14 articles about Amarin Pharmaceuticals, Inc.

• FDA approves use of drug to reduce risk of cardiovascular events in certain adult patient groups

  12/13/2019

  The U.S. Food and Drug Administration approved the use of Vascepa as an adjunctive therapy to reduce the risk of cardiovascular events among adults with elevated triglyceride levels of 150 milligrams per deciliter or higher.

• Could a Fish Oil Backlash Wash Out Amarin Pharmaceuticals, Inc.?

  11/19/2012

• Amarin Pharmaceuticals, Inc. Appoints Declan Doogan to New Position of President-Research and Development

  4/10/2007

• Amarin Pharmaceuticals, Inc. Appoints Paul F. Duffy to New Position of President - U.S. Commercial Operations

  4/3/2007

• Board Director Purchases Shares in Amarin Pharmaceuticals, Inc.

  3/15/2007

• Amarin Pharmaceuticals, Inc. Appoints Professor William Hall as Non-Executive Director

  2/27/2007

• Amarin Pharmaceuticals, Inc. Announces Completion Of Two Phase III Trials With Miraxion In Huntington's Disease

  2/5/2007

• Amarin Pharmaceuticals, Inc. Announces Grant Of Patent In The United States For Miraxion In Huntington's Disease

  10/11/2006

• Amarin Pharmaceuticals, Inc. To Present At UBS Warburg Global Life Sciences Conference

  9/25/2006

• Amarin Pharmaceuticals, Inc. Completes Target Patient Enrollment In North American Phase III Trial Of Miraxion(TM) In Huntington's Disease

  6/29/2006

• Amarin Pharmaceuticals, Inc. Acquires Parkinson's Disease Drug Candidate

  5/17/2006

• Amarin Pharmaceuticals, Inc. Reports Fourth Quarter And Full Year 2005 Results

  2/9/2006

• Amarin Pharmaceuticals, Inc. Reports Preliminary Results From Parkinson's Disease Pre-Clinical Program Using Miraxion

  1/10/2006

• Amarin Pharmaceuticals, Inc. Announces Commencement Of European Pivotal Phase III Clinical Trial For Miraxion In Huntington's Disease

  12/15/2005